Do you want to read an article? Please log in or register.
Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
COPD
Related content
COPD
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Respir Res.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA
doi: 10.1186/s12931-018-0724-0.
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>
doi: 10.1016/
RECOMMENDED
Further Publications
Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
Adv Ther.
Svedsater H, Doll HA, Macey J, Miles G, Bradshaw L, Vanya M
doi: 10.1007/s12325-018-0760-7.
RECOMMENDED
COPD
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D
doi: 10.1186/s12931-020-01360-w.
Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials
J Asthma
Kerwin E, Barnes N, Gibbs M, Leather D, Forth R, Jacques L, Yates LJ
doi: 10.1080/02770903.
COPD
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Int J Chron Obstruct Pulmon Dis.
Beeh KM, Beier J, Candler H, Wittig T
doi: 10.2147/COPD.S11765
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice
N Engl J Med.
Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A; Salford
doi: 10.1056/NEJMoa1608033
COMMENTED
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial
Respirology.
Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators
doi: 10.1111/resp.13374.
COPD
Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial
Respir Res.
Sivapalan P, Jørgensen NR, Mathioudakis AG, Eklöf J, Lapperre T, Ulrik CS, Andreassen HF, Armbruster K, Sivapalan P, Janner J, Godtfredsen N, Weinreich UM, Nielsen TL, Seersholm N, Wilcke T, Schuetz P, Klausen TW, Marså K, Vestbo J, Jensen JU
doi: 10.1186/s12931-020-01531-9.